InvestMoat
Healthcare | mRNA Vaccines + OncologyPhase 3 Cancer VaccineCOVID Revenue Reset

Moderna, Inc.

MRNA~$80B capAnalysed Oct 26

Speculative Buy

Higher Risk / Asymmetric Reward

62
Moat65
Growth73
Val55
0255075100

Combined average of Moat (AI Resilience), Growth, and Valuation scores.

65/100

Moderna's moat is an mRNA design-and-manufacture platform that just produced the first positive Phase 3 individualized neoantigen cancer therapy — intismeran autogene, 50/50 with Merck — sitting on top of a still-resetting respiratory vaccine franchise. The platform is real and now clinically validated in adjuvant melanoma; it is not a patent fortress, and COVID IP was just settled for $950 million.

The competitive position rests on individualized neoantigen manufacturing plus a 50/50 Merck oncology collaboration, not on COVID vaccine share which has already collapsed:

  • Intismeran: first Phase 3 mRNA cancer therapy: On August 19, 2026 Merck and Moderna reported that INTerpath-001 (1,137 patients, 2:1, resected stage IIB–IV melanoma) met recurrence-free survival and distant metastasis-free survival at a pre-specified interim versus KEYTRUDA alone — the first Phase 3 win for an individualized neoantigen therapy and the first to show a clinically meaningful improvement over KEYTRUDA monotherapy in adjuvant melanoma. Hazard ratios were not disclosed; the full data are LBA1 in the ESMO 2026 Presidential Symposium on October 24, with a Phase 1 pancreatic poster and the INTerpath-014 stage I NSCLC design following that week. Five-year Phase 2b (KEYNOTE-942) showed a 49% cut in recurrence or death (HR 0.51) and a 59% cut in distant metastasis or death (HR 0.411). Nine Phase 2/3 INTerpath trials are underway across melanoma, NSCLC, bladder cancer and renal cell carcinoma; adjuvant RCC Phase 2 is fully enrolled and may be the next readout.
  • Personalized manufacturing, 50/50 with Merck: Each intismeran dose is built from a patient's tumor mutational signature — synthetic mRNA coding for up to 34 neoantigens inside Moderna's LNP. That workflow (sequencing → design → GMP batch per patient) is the switching cost, and it is also the scale risk: commercial adjuvant melanoma would require industrializing one-lot-per-patient manufacturing. Merck paid $250 million in 2022 to exercise its option; costs and profits are shared equally worldwide. Moderna does not own the oncology P&L outright, but it keeps the manufacturing node and the platform IP.
  • The rival read: BioNTech's colorectal stop: On August 28, 2026 BioNTech and Genentech terminated the Phase 2 BNT122-01 trial of autogene cevumeran, their individualized mRNA therapy, in ctDNA-positive resected colorectal cancer after the DSMB saw a numerical overall-survival imbalance; that study gave the therapy alone, without a checkpoint inhibitor. Their pancreatic Phase 2 with checkpoint inhibition and chemotherapy continues. The read for Moderna is that individualization alone is not a tumor-agnostic win: every positive intismeran result so far is in combination with KEYTRUDA, which Merck owns, so the second tumor type is a real test rather than a formality.
  • Respiratory franchise after the COVID cliff: FY2025 revenue was $1.9 billion after the pandemic unwind. Spikevax, mNEXSPIKE and mRESVIA remain the cash products; mFLUSIVA (mRNA-1010) won FDA approval on August 5, 2026 for adults 50+ (traditional 50–64, accelerated 65+) for the 2026–27 season, and mCOMBRIAX (flu+COVID) is authorized in the EU. 2026 guidance is up to +10% growth, ~50/50 US/international, with ~55% of H2 recognized in Q3. Norovirus (mRNA-1403) missed early-success criteria at the Phase 3 interim and needs another cohort. The respiratory book funds the oncology build; it is not a growth engine on the scale of 2021–22.
  • IP settlement and remaining legal drag: H1 2026 cost of sales included $884 million of royalties tied to a $950 million Arbutus/Genevant settlement paid in July. That cleared the largest LNP-patent overhang but left potential additional exposure of up to $1.3 billion and other ongoing litigation. Regulatory lock-in on approved vaccines is real; the COVID IP estate is no longer a free option.

Moderna is a net beneficiary of AI in the narrow sense that sequence-to-neoantigen design and trial operations compress with better models — that strengthens the process, it does not create a new moat. The AI-resilient pillars that actually matter are regulatory approvals on the respiratory franchise and the still-unapproved but now Phase-3-positive oncology dataset; both are intact, not strong. Talent and process knowledge are contestable. The COVID IP settlement showed the vulnerable side: LNP patents were never exclusive. Durability in the AI era depends on converting intismeran into approved, guideline-embedded therapy, not on software-style switching costs.

65.0 resilient · 65.0 vulnerable · 80/20 = 65.0 · = 65

Open a moat to read its note.

AI-Vulnerable Moats2 intact · 3 N/A
AI-Resilient Moats4 intact · 3 N/A

Moderna's moats hold. An intismeran approval would add a new oncology franchise to the regulatory and data pillars, but the filing depends on overall-survival data and the RCC readout that the keyRisk names, so no widening is called before it is approved. The respiratory approvals and government contracts stay intact against Pfizer, BioNTech and the large-pharma mRNA groups.

No moat trending · 65 holds

INTerpath program — what Phase 3 melanoma does and does not settle

Nine trials, one readout

INTerpath-001 is the first positive Phase 3 for an individualized neoantigen therapy. It de-risks adjuvant melanoma. It does not, by itself, de-risk NSCLC, bladder, kidney, or the manufacturing of one lot per patient at commercial scale.

Settled today

Intismeran + KEYTRUDA beat KEYTRUDA alone on RFS and DMFS in resected stage IIB–IV melanoma at a pre-specified interim. Safety matched prior studies. Merck and Moderna will take the package to a medical meeting and to regulators.

Still unpublished

Phase 3 hazard ratios, p-values and subgroup detail were withheld until ESMO 2026 (LBA1, Presidential Symposium, October 24; Moderna investor webcast the same day). Phase 2b five-year data (HR 0.51 RFS, HR 0.411 DMFS) set the bar investors will compare against. Overall survival continues per protocol.

Next tumor tests

Fully enrolled: adjuvant RCC Phase 2 (possible year-end 2026; flagged as potentially registrational) and adjuvant muscle-invasive bladder Phase 2. Also running: high-risk Stage 1 NSCLC Phase 3 (monotherapy and with KEYTRUDA QLEX) plus further melanoma, lung and bladder cohorts.

Economics

Worldwide 50/50 cost and profit share with Merck after the 2022 $250M option exercise. Peak-sales talk is multi-billion; Moderna keeps half, and only after approval, scale manufacturing and payer coverage. Melanoma incidence in the US is ~112,000 new cases in 2026 — adjuvant stage IIB–IV is a slice of that, not the whole TAM.

Is Moderna stock a buy?

We rate Moderna Speculative Buy, with a composite score of 62/100: moat 65, growth 73 and valuation 55. The valuation score is struck against our bear, base and bull targets and moves with the price.

What is Moderna's moat?

Moderna scores 65/100 on moat. Moderna's moat is an mRNA design-and-manufacture platform that just produced the first positive Phase 3 individualized neoantigen cancer therapy — intismeran autogene, 50/50 with Merck — sitting on top of a still-resetting respiratory vaccine franchise.

How fast is Moderna expected to grow?

We estimate 12-20% a year over the next three to five years, for a growth score of 73/100.

What is Moderna's price target?

Our base case is $145, with $85 in the bear case and $250 in the bull case.